|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.25 - 00:39
|
What Analysts Are Saying About Myriad Genetics Stock (Benzinga)
|
|
|
Latest Ratings for MYGN
DateFirmActionFromTo Nov 2021SVB LeerinkMaintainsMarket Perform Jun 2021Raymond JamesInitiates Coverage OnMarket Perform Jun 2021Goldman SachsInitiates Coverage OnSell
View More Analyst Ratings for MYGN
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.04.25 - 22:06
|
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 (Business Wire)
|
|
|
New QIAseq panels launched for use on next-generation sequencers to boost analysis of over 700 genes for comprehensive genomic profiling in research and clinical applications
Advancing key partnerships: New QIAseq panels to be added to Element Bioscience's Trinity workflow, new assay in development with Myriad Genetics planned for launch in 2025
QIAGEN Digital Insights introduces a free, feature-limited version of Human Somatic Mutation Database, making vital genomic insights more accessible to global research community
VENLO, Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling.
These new developments will be showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30 in Chicago.
Important updates include a new set of QIAseq panels for comprehensive genomic profiling (CGP) and a new QIAcuit...
|
|
|
22.04.25 - 22:06
|
QIAGEN treibt Krebsgenomik-Profiling voran und stellt neue Produkte und Partnerschaften auf dem Jahrestreffen der American Association for Cancer Research 2025 vor (Business Wire)
|
|
|
Neue QIAseq-Panels für den Einsatz auf Next-Generation-Sequenzierern für die verbesserte Analyse von über 700 Genen zum umfassenden Genom-Profliling in Forschung und klinischen Anwendungen
Ausbau wichtiger Partnerschaften: Integration neuer QIAseq-Panels in den Trinity-Workflow von Element Bioscience; Markteinführung eines neuen, sich in Entwicklung mit Myriad Genetics befindlichen Assays für 2025 geplant
QIAGEN Digital Insights führt eine kostenlose Version der Human Somatic Mutation Database mit eingeschränktem Funktionsumfang ein, um der globalen Forschungsgemeinschaft den Zugang zu wichtigen genomischen Erkenntnissen zu erleichtern
VENLO, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine Reihe von Produkt- und Kooperationsneuheiten bekannt gegeben, mit denen das Portfolio für das Genom-Profiling von Krebserkrankungen ausgebaut werden soll.
Diese neuen Entwicklungen werden auf dem Jahrestreffen der American Association for Cancer Research (AACR...
|
|
|
|
|
|
|
|
|
08.04.25 - 22:18
|
Myriad Genetics Announces Inducement Awards (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly's entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
